KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) FCF Margin (2020 - 2023)

AbCellera Biologics' FCF Margin history spans 4 years, with the latest figure at 370.87% for Q4 2023.

  • For the quarter ending Q4 2023, FCF Margin fell 45712.0% year-over-year to 370.87%, compared with a TTM value of 2150.17% through Sep 2024, down 201483.0%, and an annual FY2024 reading of 648.4%, down 33065.0% over the prior year.
  • FCF Margin for Q4 2023 was 370.87% at AbCellera Biologics, down from 309.7% in the prior quarter.
  • The five-year high for FCF Margin was 526.37% in Q2 2022, with the low at 484.31% in Q1 2023.
  • Average FCF Margin over 4 years is 27.53%, with a median of 23.84% recorded in 2021.
  • Year-over-year, FCF Margin surged 23891bps in 2021 and then crashed -59894bps in 2023.
  • Tracing ABCL's FCF Margin over 4 years: stood at 0.11% in 2020, then plummeted by -17315bps to 18.76% in 2021, then soared by 560bps to 86.25% in 2022, then plummeted by -530bps to 370.87% in 2023.
  • Per Business Quant, the three most recent readings for ABCL's FCF Margin are 370.87% (Q4 2023), 309.7% (Q3 2023), and 72.57% (Q2 2023).